Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis

Ilir Agalliu, Marta San Luciano, Anat MirelmanMD, Nir Giladi, Bjorg Waro, Jan Aasly, Rivka Inzelberg, Sharon Hassin-Baer, Eitan Friedman, Javier Ruiz-Martinez, Jose Felix Marti-Masso, Avi Orr-Urtreger, Susan Bressman, Rachel Saunders-Pullman

Research output: Contribution to journalArticle

31 Citations (Scopus)

Abstract

IMPORTANCE: Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies. OBJECTIVES: To analyze pooled data from 5 centers to further examine the association between LRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies. DESIGN, SETTING, AND PARTICIPANTS: Clinical, demographic, and genotyping data aswell as cancer outcomes were pooled from 1549 patients with PD recruited across 5movement disorders clinics located in Europe, Israel, and the United States. Associations between LRRK2 G2019S mutation and the outcomes were examined using mixed-effects logistic regression models to estimate odds ratios (ORs) and 95%CIs. Models were adjusted for age and ethnicity (Ashkenazi Jewish vs others) as fixed effects and study center as a random effect. MAIN OUTCOMES AND MEASURES: All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer. RESULTS: The overall prevalence of the LRRK2 G2019S mutation was 11.4%among all patients with PD. Mutation carriers were younger at PD diagnosis and more likely to be women (53.1%) and of Ashkenazi Jewish descent (76.8%) in comparison with individuals who were not mutation carriers. The LRRK2 G2019S mutation carriers had statistically significant increased risks for nonskin cancers (OR, 1.62; 95%CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95%CI, 1.07-3.26) and breast cancer (OR, 2.34; 95%CI, 1.05-5.22) in comparison with noncarriers. There were no associations with other cancers. There were no major statistically significant differences in the results when the data were stratified by Ashkenazi Jewish ethnicity; however, there was some evidence of heterogeneity across centers. CONCLUSIONS AND RELEVANCE: This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. Larger prospective cohorts or family-based studies investigating associations between LRRK2 mutations and cancer among patients with PD are warranted to better understand the underlying genetic susceptibility between PD and hormone-related cancers.

Original languageEnglish (US)
Pages (from-to)58-65
Number of pages8
JournalJAMA Neurology
Volume72
Issue number1
DOIs
StatePublished - Jan 1 2015

Fingerprint

Parkinson Disease
Mutation
Neoplasms
Odds Ratio
Hormones
Breast Neoplasms
Cancer
Parkinson's Disease
Carrier
Logistic Models
Israel
Genetic Predisposition to Disease
Smoking
Demography

ASJC Scopus subject areas

  • Arts and Humanities (miscellaneous)
  • Clinical Neurology

Cite this

Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis. / Agalliu, Ilir; San Luciano, Marta; MirelmanMD, Anat; Giladi, Nir; Waro, Bjorg; Aasly, Jan; Inzelberg, Rivka; Hassin-Baer, Sharon; Friedman, Eitan; Ruiz-Martinez, Javier; Marti-Masso, Jose Felix; Orr-Urtreger, Avi; Bressman, Susan; Saunders-Pullman, Rachel.

In: JAMA Neurology, Vol. 72, No. 1, 01.01.2015, p. 58-65.

Research output: Contribution to journalArticle

Agalliu, I, San Luciano, M, MirelmanMD, A, Giladi, N, Waro, B, Aasly, J, Inzelberg, R, Hassin-Baer, S, Friedman, E, Ruiz-Martinez, J, Marti-Masso, JF, Orr-Urtreger, A, Bressman, S & Saunders-Pullman, R 2015, 'Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis', JAMA Neurology, vol. 72, no. 1, pp. 58-65. https://doi.org/10.1001/jamaneurol.2014.1973
Agalliu, Ilir ; San Luciano, Marta ; MirelmanMD, Anat ; Giladi, Nir ; Waro, Bjorg ; Aasly, Jan ; Inzelberg, Rivka ; Hassin-Baer, Sharon ; Friedman, Eitan ; Ruiz-Martinez, Javier ; Marti-Masso, Jose Felix ; Orr-Urtreger, Avi ; Bressman, Susan ; Saunders-Pullman, Rachel. / Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis. In: JAMA Neurology. 2015 ; Vol. 72, No. 1. pp. 58-65.
@article{3fe85e1252be42e8a9f0874fefda64c1,
title = "Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis",
abstract = "IMPORTANCE: Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies. OBJECTIVES: To analyze pooled data from 5 centers to further examine the association between LRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies. DESIGN, SETTING, AND PARTICIPANTS: Clinical, demographic, and genotyping data aswell as cancer outcomes were pooled from 1549 patients with PD recruited across 5movement disorders clinics located in Europe, Israel, and the United States. Associations between LRRK2 G2019S mutation and the outcomes were examined using mixed-effects logistic regression models to estimate odds ratios (ORs) and 95{\%}CIs. Models were adjusted for age and ethnicity (Ashkenazi Jewish vs others) as fixed effects and study center as a random effect. MAIN OUTCOMES AND MEASURES: All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer. RESULTS: The overall prevalence of the LRRK2 G2019S mutation was 11.4{\%}among all patients with PD. Mutation carriers were younger at PD diagnosis and more likely to be women (53.1{\%}) and of Ashkenazi Jewish descent (76.8{\%}) in comparison with individuals who were not mutation carriers. The LRRK2 G2019S mutation carriers had statistically significant increased risks for nonskin cancers (OR, 1.62; 95{\%}CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95{\%}CI, 1.07-3.26) and breast cancer (OR, 2.34; 95{\%}CI, 1.05-5.22) in comparison with noncarriers. There were no associations with other cancers. There were no major statistically significant differences in the results when the data were stratified by Ashkenazi Jewish ethnicity; however, there was some evidence of heterogeneity across centers. CONCLUSIONS AND RELEVANCE: This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. Larger prospective cohorts or family-based studies investigating associations between LRRK2 mutations and cancer among patients with PD are warranted to better understand the underlying genetic susceptibility between PD and hormone-related cancers.",
author = "Ilir Agalliu and {San Luciano}, Marta and Anat MirelmanMD and Nir Giladi and Bjorg Waro and Jan Aasly and Rivka Inzelberg and Sharon Hassin-Baer and Eitan Friedman and Javier Ruiz-Martinez and Marti-Masso, {Jose Felix} and Avi Orr-Urtreger and Susan Bressman and Rachel Saunders-Pullman",
year = "2015",
month = "1",
day = "1",
doi = "10.1001/jamaneurol.2014.1973",
language = "English (US)",
volume = "72",
pages = "58--65",
journal = "JAMA Neurology",
issn = "2168-6149",
publisher = "American Medical Association",
number = "1",

}

TY - JOUR

T1 - Higher frequency of certain cancers in LRRK2 G2019S mutation carriers with Parkinson disease a pooled analysis

AU - Agalliu, Ilir

AU - San Luciano, Marta

AU - MirelmanMD, Anat

AU - Giladi, Nir

AU - Waro, Bjorg

AU - Aasly, Jan

AU - Inzelberg, Rivka

AU - Hassin-Baer, Sharon

AU - Friedman, Eitan

AU - Ruiz-Martinez, Javier

AU - Marti-Masso, Jose Felix

AU - Orr-Urtreger, Avi

AU - Bressman, Susan

AU - Saunders-Pullman, Rachel

PY - 2015/1/1

Y1 - 2015/1/1

N2 - IMPORTANCE: Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies. OBJECTIVES: To analyze pooled data from 5 centers to further examine the association between LRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies. DESIGN, SETTING, AND PARTICIPANTS: Clinical, demographic, and genotyping data aswell as cancer outcomes were pooled from 1549 patients with PD recruited across 5movement disorders clinics located in Europe, Israel, and the United States. Associations between LRRK2 G2019S mutation and the outcomes were examined using mixed-effects logistic regression models to estimate odds ratios (ORs) and 95%CIs. Models were adjusted for age and ethnicity (Ashkenazi Jewish vs others) as fixed effects and study center as a random effect. MAIN OUTCOMES AND MEASURES: All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer. RESULTS: The overall prevalence of the LRRK2 G2019S mutation was 11.4%among all patients with PD. Mutation carriers were younger at PD diagnosis and more likely to be women (53.1%) and of Ashkenazi Jewish descent (76.8%) in comparison with individuals who were not mutation carriers. The LRRK2 G2019S mutation carriers had statistically significant increased risks for nonskin cancers (OR, 1.62; 95%CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95%CI, 1.07-3.26) and breast cancer (OR, 2.34; 95%CI, 1.05-5.22) in comparison with noncarriers. There were no associations with other cancers. There were no major statistically significant differences in the results when the data were stratified by Ashkenazi Jewish ethnicity; however, there was some evidence of heterogeneity across centers. CONCLUSIONS AND RELEVANCE: This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. Larger prospective cohorts or family-based studies investigating associations between LRRK2 mutations and cancer among patients with PD are warranted to better understand the underlying genetic susceptibility between PD and hormone-related cancers.

AB - IMPORTANCE: Patients with Parkinson disease (PD) who harbor LRRK2 G2019S mutations may have increased risks of nonskin cancers. However, the results have been inconsistent across studies. OBJECTIVES: To analyze pooled data from 5 centers to further examine the association between LRRK2 G2019S mutation and cancer among patients with PD and to explore factors that could explain discrepancies. DESIGN, SETTING, AND PARTICIPANTS: Clinical, demographic, and genotyping data aswell as cancer outcomes were pooled from 1549 patients with PD recruited across 5movement disorders clinics located in Europe, Israel, and the United States. Associations between LRRK2 G2019S mutation and the outcomes were examined using mixed-effects logistic regression models to estimate odds ratios (ORs) and 95%CIs. Models were adjusted for age and ethnicity (Ashkenazi Jewish vs others) as fixed effects and study center as a random effect. MAIN OUTCOMES AND MEASURES: All cancers combined, nonskin cancers, smoking-related cancers, hormone-related cancers, and other types of cancer. RESULTS: The overall prevalence of the LRRK2 G2019S mutation was 11.4%among all patients with PD. Mutation carriers were younger at PD diagnosis and more likely to be women (53.1%) and of Ashkenazi Jewish descent (76.8%) in comparison with individuals who were not mutation carriers. The LRRK2 G2019S mutation carriers had statistically significant increased risks for nonskin cancers (OR, 1.62; 95%CI, 1.04-2.52), hormone-related cancers (OR, 1.87; 95%CI, 1.07-3.26) and breast cancer (OR, 2.34; 95%CI, 1.05-5.22) in comparison with noncarriers. There were no associations with other cancers. There were no major statistically significant differences in the results when the data were stratified by Ashkenazi Jewish ethnicity; however, there was some evidence of heterogeneity across centers. CONCLUSIONS AND RELEVANCE: This multinational study from 5 centers demonstrates that LRRK2 G2019S mutation carriers have an overall increased risk of cancer, especially for hormone-related cancer and breast cancer in women. Larger prospective cohorts or family-based studies investigating associations between LRRK2 mutations and cancer among patients with PD are warranted to better understand the underlying genetic susceptibility between PD and hormone-related cancers.

UR - http://www.scopus.com/inward/record.url?scp=84921044518&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84921044518&partnerID=8YFLogxK

U2 - 10.1001/jamaneurol.2014.1973

DO - 10.1001/jamaneurol.2014.1973

M3 - Article

C2 - 25401981

AN - SCOPUS:84921044518

VL - 72

SP - 58

EP - 65

JO - JAMA Neurology

JF - JAMA Neurology

SN - 2168-6149

IS - 1

ER -